


Anderssohn M, McLachian S, Luneburg N, Robertson C, Schwedhelm E, Williamson et al., 2014, Genetic And Environmental Determinants of Dimethylarginines and Association With Cardiovascular Disease in Patients With Type 2 Diabetes, Care diabetesjournals, 37: 846-54.


Beltowski J and Kedra A, 2006, Asymmetric dimethylarginine (ADMA) as a target for phamacotherapy, Pharmacological Reports, 58: 159-78.


Kaku K, 2010, Pathophysiology of Type 2 Diabetes and Its Treatment Policy, JMAJ, 53(1): 41-6


Marcovecchio ML, Widmer B, Dunger DB, Dalton RN, 2011, Asymmetric
Dimethylarginine in Young People with Type 1 Diabetes: A Paradoxical

Muonio DM and Newgard CB, 2008, Molecular And Metabolic Mechanisms Of
Insulin Resistance And B-Cell Failure In Type 2 Diabetes, *Molecular Cell

Nagamani G, Putcha V, Lind M, and Sridhar GR, 2015, Menstruation in Diabetes
Mellitus: A Study from South India, *Journal of Diabetes Research and
Therapy*, p. 1-3.

Nakhjavani M, Jafari K, Esteghamati A, Khalilzadeh O, Asgarani F, Anari AG,
2010, ADMA is a Correlatate of Insulin Resistance in Early-Stage Diabetes
Independent of hs-CRP and Body Adiposity, *Annales d’Endocrinologie*, 71:
p: 303-308.

Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al., 2014,
Global, Regional, and National Prevalence of Overweight and Obesity in
Children and Adults During 1980-2013: Systematic Analysis for the Global

Perkeni, 2011, Perkumpulan Endokrinologi Indonesia, Konsensus Pengendalian dan
Pencegahan Diabetes Mellitus Tipe 2 di Indonesia 2011, hh: 4-10.

Polonsky KS and Burant CF, 2016, Type 2 Diabetes Mellitus, in: *Williams
Textbook of Endocrinology*, editor Melmed S, Polonsky KS, Larsen PR,


RISKESDA, 2013, Badan Penelitian Dan Pengembangan Kesehatan Kementerian

Sacks DB and Path CB, 2006, Carbohydrates in: *Tietz Textbook Clinical Chemistry
and Molecular Diagnostics*, edit: Burtis CA, Ashwood ER, Bruns DE, Fourth

Savu O and Tirgoviste CI, 2008, Oxidative Stress Contributions to Chronic

Asymmetric Dimethylarginine Reference Intervals Determined with
Liquid Chromatography–Tandem Mass Spectrometry: Results from the

Determination of Asymmetric Dimethylarginine (ADMA) using a

Sena CM, Pereira AM, Seica R, 2013, Endothelial Dysfuction- A Mayor Mediator
of Diabetic Vascular Disease, *Biochimica et Biophysica Acta*, 18,32, p: 2216-
31


Tsikas D, 2008,” Determination of Asymmetric Dimethylarginine in Biological Fluids: a Paradigma for a Successful analytical Story”, Curr Opin Nutr Metab Care, 11, p. 592-600


Willer AK, Harreiter J, and Giovanni Pacini G, 2016, Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus, Endocrine Reviews 37: 278–316.
Yamagishi S, Ueda S, Okuda S, 2007, Possible Involvement of Crosstalk Between Advanced Glycation End Products (AGEs) and Asymmetric Dimethylarginine (ADMA), an Endogenous Nitric Oxide Synthase Inhibitor In Accelerated Atherosclerosis in Diabetes, Med Hypotheses; 69, p: 922-4.